© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Butenafine Hydrochloride has roots in the search for better options to fight fungal infections of the skin. Many of us recall a time when over-the-counter antifungals either worked slowly or left us with lingering symptoms. Researchers in Japan, frustrated with those results, decided to chase a molecule that could attack dermatophytes directly and quickly. In the late 1980s, scientists at Sumitomo Chemical Company brought butenafine to life, running it through thorough lab testing before launching it in Asia through prescription and, eventually, OTC channels. It didn’t take long before word spread to North America and Europe, where medical professionals recommended butenafine for tougher tinea infections on the feet, body, and groin. As the spread of superficial fungal infections climbed, particularly among active folks and the elderly, this new antifungal became a welcome addition to the toolkit. A journey from laboratory curiosity to trusted skin treatment—rooted in science, shaped by need.
People often ask what makes this medicine different from others at the pharmacy. Butenafine Hydrochloride targets the fungus right at its source. Topical creams typically include 1% of the drug and deliver relief for athlete’s foot and ringworm. Its broad spectrum covers both dermatophytes and some yeasts, filling a gap where other agents fall short. The ointment spreads without a strong smell, doesn’t dry out skin, and stays melded to the infected area. For families with kids and those with sensitive skin, the gentle profile matters every bit as much as clinical studies. For many, these qualities mean choosing butenafine over older remedies that sting or require longer applications. Doctors look past marketing and dig into public health data—the strong performance in clearing infections and minimizing relapses says a lot about its staying power.
If you open the tube and peek inside, you see a standard white cream—straightforward, no unnecessary fragrances. The science behind that simple cream tells a bigger story. Butenafine Hydrochloride appears as a white to off-white powder before it’s mixed into products. The chemical’s solubility in alcohol and ether allows formulation chemists to blend it with other ingredients that improve skin absorption. It has a melting range above 170°C, a sign of pure chemistry and a stable structure unlikely to degrade on the shelf. Weighing in at about 349 g/mol, with the empirical formula C23H27N•HCl—this isn’t just a jumble of letters to a chemist. It’s a signature that tells you how the drug binds and disrupts fungal cell membranes. The crystalline nature keeps batch quality reliable, so every tube on store shelves delivers the same safe, predictable performance.
Getting a product onto pharmacy shelves takes more than a good idea—it requires rigid standards. Butenafine Hydrochloride creams on the market come as 1% topical formulations, sealed in airtight packaging, always carrying batch numbers and expiration dates for tracking. Packaging calls out not only the drug content, but also warnings for allergies, storage instructions, and directions for use. Pharmacies and hospitals rely on this detailed labeling to catch issues before they start. Technical documents specify minimum purity thresholds, shelf life, storage at 20-25°C, and resistance to light and humidity. These standards don’t spring from nowhere. They’re built on reaction to decades of medicine cabinet mishaps, recalls, and contamination scares. Quality control isn’t optional, particularly for skin preparations in long-term care, pediatric, or immunocompromised settings, where every misstep carries real human risk.
Churning out high-quality butenafine isn’t simple. Chemists start with naphthalene derivatives and carefully tweak their structure through multi-step synthesis, protecting and deprotecting chemical groups at every step. After forming the basic skeleton, they introduce a benzyl group to the ring and stitch on a methyl group, forming the unique tertiary amine. The transformation into its hydrochloride salt stabilizes the compound for long shelf life and moisture resistance. Each stage involves tough purification, often by recrystallization or chromatography, leaving no room for leftover solvents or contaminants. Final products pass physicochemical testing, spectrum analysis, and solubility assessments. Industrial plants pump out kilogram batches, but QC managers send regular samples to the lab, watching for variations that could disturb clinical outcomes. With antibiotic resistance and cross-contamination on the rise, production lines take safety, sterility, and environmental impact seriously—from raw materials to the tube in a patient's hand.
Butenafine owes its antifungal punch to the way it disrupts fungal ergosterol synthesis. In the lab, scientists tweak its structure to explore whether minor changes make it fight more species, dissolve faster, or avoid skin irritation. The basic tertiary amine and aromatic rings become the focus of research. Adding side chains, changing halogen atoms, or swapping benzyl groups lets chemists craft analogs and compare biological outcomes. Some derivatives show promise in vitro, though not all make it to commercial production. Modification gives researchers hope for treating tougher infections or cutting down on resistance, while teaching the industry about what chemical designs translate smoothly from glassware to clinical practice. Each changed molecule gets scrutinized in animal studies and preclinical trials, as regulatory agencies ramp up scrutiny against medication missteps.
Walking down any pharmacy aisle, you notice how the same compound hides behind different brand names and generics. Butenafine Hydrochloride goes by names like Lotrimat Ultra, Mentax, and several store generics—all built on the same active base. Chemical texts label it by synonyms: N-(4-tert-Butylbenzyl)-N-methyl-1-naphthalenemethanamine hydrochloride. This can make research confusing, especially for those who skim over differences between nomenclature systems or language regions. Families trust a familiar brand, but regulatory agencies demand manufacturers prove bioequivalence. International sales add layers of complexity, as rules surrounding naming, packaging, and advertising keep shifting. Through it all, the chemical fingerprint never changes—it’s the same agent clearing fungal rashes in clinics worldwide.
Doctors and pharmacists care about what goes on your skin as much as what you put in your mouth. Butenafine Hydrochloride creams score high marks for safety, with rare reports of irritation or sensitivity. Labels stress “for external use only” to prevent accidental ingestion, and patient handouts warn about contact with eyes and mucous membranes. Facilities handling the pure powder suit up with gloves, goggles, and ventilation; airborne dust poses a mild respiratory risk. Manufacturing plants stick to Good Manufacturing Practices, tracking temperature, humidity, and contamination throughout. End-user safety also depends on honest communication—teaching patients to finish the suggested course and recognize adverse reactions early. As more people self-treat without doctor visits, the burden falls on companies to print warnings, instructions, and expiration dates in clear, approachable language. Staying proactive about safety isn’t bureaucracy. It’s about trust—between manufacturer, clinician, and the person at the bathroom sink.
For most, the word “antifungal” brings up foot powders and sprays at the drugstore. Butenafine finds its place in a world far wider than that. Hospitals use it for tinea infections that bother elderly bed-bound patients. Athletes working hard in training rooms rub it onto sweaty, persistent infections after every shower. For workers in tropical climates and families in crowded living spaces, the risk of ringworm or jock itch is never far off. Skin clinics suggest butenafine for stubborn rashes where other drugs failed, and parents dab it onto their kids where pets passed along infections. Its reach goes further—dermatologists examine its potential use against some uncommon yeast and mold infections, pushing the boundaries set by earlier generations of antifungal drugs. This versatility helps rural clinics, sports teams, nursing homes, and supermarkets stock something proven—side-stepping the constant search for the “next best thing.”
The heart of medical progress beats in university labs and pharmaceutical R&D facilities. Butenafine hasn’t slipped into dormancy. Teams around the world work to look beyond skin conditions, thinking outside the box. Scientists study new ointment bases that could deliver the active agent even deeper into nail beds without wrecking nearby skin. Some research groups try out butenafine analogs against drug-resistant Candida or Malassezia and even run tests to see if it helps treat certain chronic wounds. Early-stage studies stretch the usual definitions of what an “antifungal” does, seeking overlap with inflammation, wound healing, and immune modulation. Clinical trials follow strict guidelines and collect hard evidence before anyone markets a new use—too much history has shown the cost of racing to launch without thorough safety and effectiveness screening. Every new study brings more clarity about dosage, absorption, and safety in vulnerable groups—like infants, the elderly, or people already taking heavy medications.
Before new medicines hit pharmacy shelves, toxicologists dig deep into how the compound acts in living creatures. Early research into butenafine’s safety aimed for a large therapeutic window—enough punch to kill fungus, but not so potent as to risk systemic damage. Rat and rabbit studies tracked signs for organ toxicity or cancer links and measured blood levels after skin exposure. Findings so far support topical use, with systemic absorption remaining low even under repeated application and broken skin. Like most skin drugs, rare people see mild redness, itching, or mild rash, but cases of severe allergy or systemic shock look vanishingly rare compared to other treatments. New calls for transparency mean more post-market surveillance, tracking every new report in global databases. Regulators and doctors keep a sharp eye, not just at launch but for years after, ready to yank products with hidden risks from public sale. Safety research never wraps up, especially as patient populations age, new illnesses rise, and baseline expectations for drug safety climb.
The ongoing struggle with fungal infections won’t slip away soon. Warmer climates, packed cities, and surging rates of diabetes and immunosuppression tip the scales in favor of germs. Butenafine stands out as a workhorse in current therapy, but new problems keep appearing—fungi that resist all known classes, cases that blend with bacterial skin infections, and demands for more eco-friendly, animal-friendly, and cost-effective drugs. Researchers experiment with microemulsion, liposomal, and nanoparticle delivery to cut down on application frequency and reach hard-to-penetrate zones like toenails. Pharmaceutical advances also focus on reducing inactive ingredients that slow healing or cause allergies. Meanwhile, tech-savvy patients crave personalized medicine, searching for genetic or lifestyle flags that predict treatment success or risk of relapses. From where I sit, the real challenge will not just be inventing another ingredient, but balancing innovation, safety, and access—ensuring the next generation of antifungal care isn’t just for those who can afford it, but for anyone who needs healthy skin in any corner of the world.
Fungal infections have a knack for making their presence known. Redness, itching, peeling between toes—these small annoyances disrupt daily routines. Athletes get them from locker rooms, gardeners encounter them in damp gloves, and kids pick them up running barefoot on moist grass. Doctors often see tinea versicolor, ringworm, and athlete’s foot—each a sign that fungi have moved in under the radar.
I remember looking at my own peeling, itchy toes after a week of summer hiking, searching pharmacy shelves. Butenafine Hydrochloride jumped out—not just another cream for temporary relief, but an antifungal with a clear job: break down the fungus’s ability to survive. This compound doesn’t just cover irritation; it goes after the root cause by messing with ergosterol production, a crucial piece of fungal cell walls. Cut off ergosterol, and the fungal cells start to collapse.
Topical creams with Butenafine Hydrochloride often bring relief in a matter of days. Studies back that up: short two-week regimens clear up athlete’s foot in a majority of cases. For ringworm and jock itch, the rate of improvement stays consistent, especially when people follow through with daily treatment instead of halting once symptoms fade.
Neglecting minor fungal infections leaves a door open for bigger problems. Scratching leads to skin breaks, which sets up shop for bacteria. Families dealing with recurring athlete’s foot end up passing it back and forth—shoes, baths, laundry. It becomes a cycle, especially in close quarters. Treating early and sticking to the treatment schedule doesn’t just clear up visible symptoms; it limits spread at home and keeps more people out of doctors’ waiting rooms.
Some folks worry about resistance, and with good reason. Misusing any medication, including antifungals, lets resilient fungi hang around and adapt. At the same time, Butenafine Hydrochloride’s specific mechanism targets the stubborn forms of fungus without as many side effects as oral medications, which often punish the liver. People with compromised immune systems—older adults, those with diabetes—lean on topical options like these to manage mild infections before they morph into something bigger and riskier.
Doctors remind people to dry feet well, rotate shoes, and treat the whole area—not just the spots that itch most. Butenafine Hydrochloride brings a practical, focused tool for these jobs. Washing hands after application—sounds basic, but it breaks the chain of re-infection.
Insurance covers some over-the-counter versions, but rising healthcare costs still stop patients from buying a fresh tube when they need it. Public health programs can play a bigger role by providing education on proper use and ensuring access to affordable medications.
Every family has a story about searching for relief from stubborn rashes. Solutions like Butenafine Hydrochloride remind us that science continues to make life’s little headaches easier to manage—especially for those willing to stick to the routine, trust solid research, and share what they’ve learned with the next hiker, athlete, or kid who brings home an itchy souvenir.
Butenafine Hydrochloride cream tackles fungi that cause common skin infections like athlete’s foot, jock itch, and ringworm. Over-the-counter products don’t always feel important until you’ve faced the itch, peeling, or cracked skin that comes with these conditions. Learning the right approach means faster relief, fewer recurrences, and healthier skin in the long run. Dermatologists trust Butenafine for a reason—it disrupts fungal cell membranes, cutting the infection at its root, which lets healthy tissue recover and grow back strong.
Washing and completely drying the area first removes sweat, dirt, and helps the medicine touch the infection directly. Fungi love damp, hidden spots—between toes or in skin folds—so not drying well lets problems linger. I’ve seen people struggle with long-standing athlete’s foot that clears up only after they add careful drying and twice-daily treatments. Rub in a thin layer, just enough to cover affected and surrounding skin. Extra cream won’t speed healing, but sticking with the daily routine will. With the right approach, relief starts within days, but skipping applications or stopping as soon as skin clears leads to more stubborn infections that keep coming back. Most creams ask for two to four weeks of steady use to fully get rid of hidden spores. It’s worth following through every day, even after visible symptoms fade.
Persistence pays off. Some people think the fungus has cleared once redness and itch are gone, yet stopping too soon lets the infection return. I always suggest setting a reminder or keeping the tube by your toothbrush. This small habit can make all the difference for complete recovery. Sometimes, a rash stays persistent despite careful use of over-the-counter products. If the infection spreads, gets worse, or lasts over four weeks, make an appointment with a provider. Skin changes sometimes come from bacteria or conditions like eczema, so proper evaluation ensures the treatment matches the real cause. Multiple studies highlight that fungal skin infections, including tinea pedis (athlete’s foot), rarely respond to one or two missed doses—a consistent schedule is the real fix.
Butenafine works best when paired with simple preventive steps. Keep your feet and groin dry, avoid sharing towels, and wear flip-flops in public showers or gyms. Launder socks and underwear daily during treatment, and don’t let moisture build up in shoes. In my experience, those who ignore these steps fight with endless infections. Basic hygiene turns a good cream into a full shield.
Every medicine comes with a few caveats. Mild burning or irritation sometimes shows up. Allergic reactions—like severe swelling, hives, or trouble breathing—demand medical care right away. Avoid using the cream on broken skin, eyes, or mouth, and don’t combine it with other topical treatments unless cleared by a professional. If in doubt, consult a pharmacist or dermatologist. Published guidelines from trusted sources like the American Academy of Dermatology emphasize sticking to the label and being quick to seek further help if symptoms persist or worsen.
Smart use of Butenafine Hydrochloride isn’t complicated, but missing small steps can prolong discomfort. Using evidence-backed advice, personal reminders, and a little patience transforms an easily missed routine into lasting relief. With careful treatment, prevention, and occasional professional input, fungal skin infections don’t get the final say.
Anyone who’s ever picked up an over-the-counter antifungal cream will probably see butenafine hydrochloride somewhere in the ingredients. Plenty of athletes’ foot creams, ringworm treatments, and jock itch remedies use it. The stuff works because it gets deep into the skin and tackles the fungus where it lives. Manufacturers make it gentle, but our skin isn’t all made the same. Some people notice side effects after they rub a bit on, and others feel fine. It doesn’t matter if the label says “topical use only.” The real test happens during use.
People usually talk about a little burning, maybe stinging, sometimes a rash. Skin around the infected spot can get red, start to itch, or feel sore. Most of the time, side effects stay mild. I’ve seen folks slather on too much, hoping faster means better results. That approach almost always backfires—higher doses send more of the medicine into the skin. The body starts pushing back, sometimes with more irritation. Every doctor I’ve chatted with has a story about that one patient who tripled the dose and regretted it. Science backs this up: post-marketing studies show mild skin irritation as the most frequent problem, with burning and itching close behind.
A small number of people notice blisters, swelling, or oozing—signs the body hates what hit it. Anyone who sees these should stop using the cream and tell their doctor. Serious allergic reactions, like facial swelling or trouble breathing, almost never happen, but the stories hit hard for the folks who face them. Health Canada and the FDA both track these, but most cases only make it to databases, not headlines. Breaking out in hives or feeling dizzy after applying the cream should set off alarm bells.
Kids under twelve don’t process medications the same way as adults. I remember my neighbor slapping antifungal on her toddler’s rash. The pediatrician had a fit. Doctors don’t love using butenafine on very young children without a reason. Pregnant folks and breastfeeding mothers should check with a medical professional before using any antifungal, not just butenafine. No long-term study proves it’s safe for a developing fetus or a breastfeeding baby. The risk often outweighs the reward in these groups.
Dragging out a fungal infection because of side effects wastes time and money. Doctors always say: use a thin layer, wash your hands after, and don’t smear butenafine over huge areas unless a doctor says to. Spreading it over broken skin or wounds almost guarantees problems. Moist, tight environments, like sweaty armpits or between toes, can make irritation worse. If a rash pops up or the treatment hurts, taking a break and getting some advice can save a lot of trouble down the road.
Some folks find terbinafine or clotrimazole works with fewer side effects. Like anything related to health, what works for one person can give someone else a rash. Pharmacies carry a mix of antifungals, and talking to a pharmacist about options doesn’t cost anything. Doctors sometimes recommend rotating treatments, especially for stubborn infections, but following their advice makes all the difference. Reading reviews online helps, but nothing beats checking in with a healthcare professional who knows your skin’s quirks.
I’ve seen plenty of people rush to fix embarrassing fungal infections. Most get through it with a few days of mild irritation. Spreading the word about side effects helps folks avoid frustration. Reading the label, using less instead of more, and talking with a healthcare provider can keep simple problems from getting complicated. These steps look simple, but they save skin—and plenty of headaches.
Butenafine hydrochloride comes up a lot in the world of over-the-counter antifungal creams. Pharmacies often stock this medicine alongside other big names like clotrimazole and terbinafine. Most folks use it to tackle athlete’s foot, jock itch, and ringworm. The cream formula spreads well, dries quickly, and usually gets results for those specific infections that live on the upper layers of the skin. It feels like pulling out the right tool for a common household repair—reliable, easy, and familiar.
I worked in a pharmacy for several years and saw people frustrated that their rash didn’t budge after days of using an antifungal cream. Many believed all fungal problems were the same. In reality, fungi get classified in different groups. Dermatophytes cause those classic round, itchy spots, but yeast (like Candida) and molds bring a whole different challenge. Butenafine packs a punch against dermatophytes and handles some yeasts. Still, it doesn't cover every possible fungus that might creep up on skin.
Where it shines: surface infections, where fungi cling to dead skin cells. Nail fungus—or infections tucked in the hair, deep in the nails, or inside the body—remains tough to treat with any cream. Applying butenafine to a nail fungus feels as futile as trying to water a plant by misting only the leaves. The medicine doesn’t penetrate deep enough. The FDA doesn’t give butenafine the green light for toenails or fingernails, so doctors usually recommend an oral drug or a different topical for those cases.
Lab studies show butenafine knocks out most Trichophyton and Epidermophyton species—those responsible for athlete’s foot and ringworm. The cream can also deal with some yeast-related rashes, like Candida, but the result varies. For deep-seated Candida infections, it falls short. Trusting one cream for everything spreads false expectations and leaves symptoms hanging around longer than anyone wants.
Mistaking bacterial or viral rashes for fungi can also trip people up and waste precious time. I’ve talked to patients using antifungals on eczema or psoriasis, hoping for results that never come. Dermatologists can often tell the difference in a single glance, but if anyone feels lost staring at a stubborn rash, a professional’s opinion saves time, money, and a lot of scratching.
The Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) both warn about antifungal resistance, not just in hospitals but out in the community. Fungus can adapt. Picking the right antifungal the first time makes it less likely the infection will linger and become even harder to stop. For skin infections easily reached by cream and likely caused by a dermatophyte, butenafine makes sense. For anything else—nail infections, recurring yeast, or mysterious skin changes—seeing a doctor leads to less frustration.
Clear education and easy ways to connect with health professionals help people react early when something looks off. As a pharmacist, directing people toward the right treatment matters more than pushing a popular tube of cream. Proper diagnosis and using butenafine where it works best keep both patients and the larger community safer from the spread of stubborn fungi.
People deal with rashes, athlete’s foot, and ringworm almost every day, especially with kids at school, daycare, or the playground. Butenafine hydrochloride, a topical antifungal cream, pops up in countless medicine cabinets across the country. Parents and expectant mothers scan labels, wondering if it’s smart to trust this medication. Safe decisions matter most when someone is small or expecting a new baby.
Young kids get exposed to all kinds of fungi, mostly on feet and hands. Doctors usually stick with topical antifungals for these problems because ointments act right where trouble starts. Butenafine hydrochloride, known mostly under brand names like Lotrimin Ultra, targets the cell walls of fungi and breaks them down. For children over two years old, pharmacy packaging marks it as suitable, though a pediatrician should always weigh in before use.
Babies and toddlers have delicate skin that absorbs more chemicals compared to adults, which raises red flags for many parents. There’s little evidence showing harsh reactions or lasting harm for kids over two using butenafine, but doctors sometimes lean toward old-fashioned treatments like clotrimazole for the very young, since they’ve stood the test of time.
During pregnancy, everything a woman uses—from shampoo to hand lotion—comes under scrutiny. Butenafine is one of those products with limited human data on pregnancy. Animal studies haven’t shown birth defects or serious complications, and topical antifungals like butenafine are generally considered low risk, because so little makes its way into the bloodstream. The U.S. Food and Drug Administration assigns it to Pregnancy Category C, which signals that caution matters: Animal studies may show some risk, but evidence in humans hasn’t offered full clarity.
In doctors’ offices, the advice usually runs like this: Stick to antifungal creams with decades of safety behind them, and only apply any medication when a genuine infection exists. Pregnant women using any topical product should talk with their doctor, especially during the first trimester, when babies develop the fastest.
From experience, parents benefit by treating fungal infections at the first sign, as an early response usually means less medicine needed. Clean socks, dry feet, and sandals after a swim help more than any cream alone. Relying on a trusted pediatrician or OB-GYN for guidance means fewer what-ifs down the road.
Plenty of families want natural, gentle options for their kids or during pregnancy. While butenafine has a good safety record for older children, and no big scares in animal studies for pregnant women, the golden rule is simple: ask questions and push for details. The medical community constantly updates guidelines, and what seemed right ten years ago may get updated after new research. Trust matters most—both in your doctor and the choices at the pharmacy.
In my own experience raising two boys prone to athlete’s foot, a fast response with a gentle treatment worked best. We used butenafine once my son turned four, after talking with our doctor, and saw quick improvement with no side effects. For expecting mothers, talking directly with a provider about safer alternatives offered peace of mind when stakes felt higher.
No single answer solves every case, but staying informed, listening to experts, and using prevention keeps families ahead of most problems. Butenafine hydrochloride sits among several options—sometimes right, sometimes best left for others to use. Knowledge and honesty make the real difference.
| Names | |
| Preferred IUPAC name | N-[4-tert-Butylbenzyl]-N-methyl-1-naphthalenemethanamine hydrochloride |
| Other names |
Mentax Butenafin Butenafin hydrochloride Butenafinum hydrochloricum |
| Pronunciation | /bjuːˈtɛn.ə.faɪn haɪˈdrɒk.lə.raɪd/ |
| Identifiers | |
| CAS Number | 130119-64-7 |
| Beilstein Reference | 1574206 |
| ChEBI | CHEBI:3137 |
| ChEMBL | CHEMBL2104747 |
| ChemSpider | 126479 |
| DrugBank | DB01007 |
| ECHA InfoCard | 100.221.339 |
| EC Number | 642-356-7 |
| Gmelin Reference | 893789 |
| KEGG | D03140 |
| MeSH | D017020 |
| PubChem CID | 125938 |
| RTECS number | NL8300000 |
| UNII | 1X50M6C4WW |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C23H27N·HCl |
| Molar mass | Molar mass of Butenafine Hydrochloride: **337.93 g/mol** |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 2.8 |
| Vapor pressure | Estimated to be 1.1 x 10^-10 mm Hg at 25°C |
| Acidity (pKa) | 7.00 |
| Basicity (pKb) | 6.62 |
| Magnetic susceptibility (χ) | -75.5e-6 cm³/mol |
| Dipole moment | 2.93 ± 0.25 D |
| Pharmacology | |
| ATC code | D01AE24 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. May cause an allergic skin reaction. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. For external use only. Avoid contact with eyes. |
| NFPA 704 (fire diamond) | 0-1-0 |
| Flash point | 112.8°C |
| Lethal dose or concentration | LD₅₀ oral (rat): >5000 mg/kg |
| LD50 (median dose) | LD50 (median dose): "2476 mg/kg (rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 20 mg |
| IDLH (Immediate danger) | Not Established |
| Related compounds | |
| Related compounds |
Naftifine Terbinafine Befunolol Tolnaftate |
